The long-term objective of the research described is to increase our understanding of the regulation of microtubule assembly and of the mechanism of action of certain anti-tumor drugs directed against tubulin, the structural subunit of microtubules. We intend to investigate the binding site of the anti-tumor drug maytansine to see its relationship to tau, one of the microtubule-associated proteins (MAPs). We also will study the dynamics of purified reconstituted microtubules consisting of tubulin and one MAP, either tau or MAP2. Such microtubules are likely to be more meaningful analogues of intracellular microtubules than the recycled microtubules used by many investigators. We will examine treadmilling and dynamic instability in these microtubules to get an idea of the role of each MAP in regulating microtubule dynamic behavior. We then will see how these parameters are perturbed by maytansine, phosphorylation (both cyclic AMP-dependent and calcium/calmodulin-dependent) of the MAPs, limited proteolysis of MAP2, and the MAP-directed anti-tumor drug estramustine phosphate. These experiments are expected to illuminate the roles of MAPs in general and tau and MAP2 in particular, in microtubule-related processes, such as transport, secretion and perhaps mitosis; they also may elucidate the mechanisms of action of the anti-tumor drugs maytansine and estramustine phosphate. We recently have described two new anti-tubulin compounds, Bis(1,8-anilinonaphthalenesulfonate) (FisANS) and 2,6-anilinoaphthalenesulfonate (2,6ANS). BisANS and 2,6ANS are, respectively, a potent inhibitor and a potent enhacer of microtubule assembly. We intend to examine the effects of BisANS and 2,6ANS on microtubule dynamics and on living cultured cells as well as on permeabilized cells. We hope to understand the in vitro and in vivo behavior of these novel anti-tubulin compounds. It is possible that these compounds, perhaps after some structural modification, could become therapeutically useful anti-tumor drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA026376-08
Application #
3167282
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1979-07-01
Project End
1990-12-31
Budget Start
1987-01-01
Budget End
1987-12-31
Support Year
8
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
School of Medicine & Dentistry
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Vent, Julia; Wyatt, Todd A; Smith, D David et al. (2005) Direct involvement of the isotype-specific C-terminus of beta tubulin in ciliary beating. J Cell Sci 118:4333-41
Dumontet, Charles; Isaac, Sylvie; Souquet, Pierre-Jean et al. (2005) Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92:E25-30
Gupta, Suvroma; Banerjee, Mithu; Poddar, Asim et al. (2005) Biphasic kinetics of the colchicine-tubulin interaction: role of amino acids surrounding the A ring of bound colchicine molecule. Biochemistry 44:10181-8
Yeh, I-Tien; Luduena, Richard F (2004) The betaII isotype of tubulin is present in the cell nuclei of a variety of cancers. Cell Motil Cytoskeleton 57:96-106
Walss-Bass, Consuelo; Kreisberg, Jeffrey I; Luduena, Richard F (2003) Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs 21:15-20
Jensen-Smith, Heather C; Eley, Jonquille; Steyger, Peter S et al. (2003) Cell type-specific reduction of beta tubulin isotypes synthesized in the developing gerbil organ of Corti. J Neurocytol 32:185-97
Perry, Brian; Jensen-Smith, Heather C; Luduena, Richard F et al. (2003) Selective expression of beta tubulin isotypes in gerbil vestibular sensory epithelia and neurons. J Assoc Res Otolaryngol 4:329-38
Jensen-Smith, Heather C; Luduena, Richard F; Hallworth, Richard (2003) Requirement for the betaI and betaIV tubulin isotypes in mammalian cilia. Cell Motil Cytoskeleton 55:213-20
Khan, Israr A; Luduena, Richard F (2003) Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain. Invest New Drugs 21:3-13
Xu, Keliang; Luduena, Richard F (2002) Characterization of nuclear betaII-tubulin in tumor cells: a possible novel target for taxol. Cell Motil Cytoskeleton 53:39-52

Showing the most recent 10 out of 67 publications